$The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients$

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients

Simple Summary The proteasome inhibitor bortezomib is currently commonly used for the treatment of multiple myeloma (MM). MicroRNAs (miRNAs) are small non-coding RNAs that play a crucial role in messenger RNA silencing and post-transcriptional regulation of gene expression. In MM, the expression of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2020-09, Vol.12 (9), p.2569, Article 2569
Hauptverfasser:	Robak, Pawel, Drozdz, Izabela, Jarych, Dariusz, Mikulski, Damian, Weglowska, Edyta, Siemieniuk-Rys, Monika, Misiewicz, Malgorzata, Stawiski, Konrad, Fendler, Wojciech, Szemraj, Janusz, Smolewski, Piotr, Robak, Tadeusz
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis Biomarkers Bone marrow Bortezomib Cancer therapies Cell cycle Disease Dosage and administration Drug resistance Drug therapy Gene expression Genetic aspects Health aspects Hematology Life Sciences & Biomedicine MicroRNA MicroRNAs miRNA Multiple myeloma Oncology Patient outcomes Proteasome inhibitors Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!